Login to Your Account



Verona's COPD drug 'robustly positive,' says CEO; phase IIb planned

By Nuala Moran
Staff Writer

Tuesday, May 10, 2016

LONDON – The initial readout points to a remarkable level of effect for Verona Pharma plc's RPL554, which has produced 60 percent additional bronchodilation on top of standard-of-care bronchodilators in a phase IIa study in moderate to severe COPD.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription